top of page



Partner
Clinical Trials
AmMax is developing first-in-class or best-in-class therapeutics targeting a range of oncology diseases with significant unmet needs . Clinical trials are needed to assess the efficacy and safety of these experimental therapies.
AmMax is executing a multi-center, global Phase 2 clinical study program to assess the efficacy and safety of AMB-05X in patients with tenosynovial giant cell tumor (TGCT).
AmMax has completed the following study in patients with tenosynovial giant cell tumor (TGCT)
If you are interested in participating in the trial or have questions, please feel free to contact us at clinical@ammaxbio.com.
bottom of page